Written by Dr. Miri Halperin Wemli and Prof. Boaz Ganor

First published by the European Biopharmaceutical Review (EBR) - Samedan Ltd / April 2015

As terrorist plots dominate the headlines, biopharma companies remain vulnerable to a wide range of intrusions motivated by criminal objectives. The industry cannot afford to neglect any data access gaps, or front door and inside job security deficiencies, to avoid compromising both employee and patient safety.